Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)

Background: Cardiovascular safety concerns for major cardiovascular events (MACE) were raised during the clinical trials of romosozumab. We aimed to evaluate the cardiovascular safety profile of romosozumab in a large pharmacovigilance database. Methods: All cases reported between January 2019 and D...

Descripción completa

Detalles Bibliográficos
Autores principales: Vestergaard Kvist, Annika, Faruque, Junaid, Vallejo-Yagüe, Enriqueta, Weiler, Stefan, Winter, Elizabeth M., Burden, Andrea M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070537/
https://www.ncbi.nlm.nih.gov/pubmed/33924496
http://dx.doi.org/10.3390/jcm10081660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070537/
https://www.ncbi.nlm.nih.gov/pubmed/33924496
http://dx.doi.org/10.3390/jcm10081660

Ejemplares similares